vs
AMERICAN SHARED HOSPITAL SERVICES（AMS）与CareDx, Inc.（CDNA）财务数据对比。点击上方公司名可切换其他公司
CareDx, Inc.的季度营收约是AMERICAN SHARED HOSPITAL SERVICES的14.0倍（$108.4M vs $7.7M）。CareDx, Inc.净利率更高（-3.8% vs -8.2%，领先4.4%）。CareDx, Inc.同比增速更快（25.2% vs -14.8%）。过去两年CareDx, Inc.的营收复合增速更高（22.7% vs 21.7%）
美国共享医院服务公司为医疗机构提供放射治疗、立体定向放射外科及诊断成像设备的整体外包解决方案，免除医院高昂的前期资本投入，主要业务覆盖北美，同时服务拉美及部分亚太地区的公立、私立医院客户。
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
AMS vs CDNA — 直观对比
营收规模更大
CDNA
是对方的14.0倍
$7.7M
营收增速更快
CDNA
高出40.0%
-14.8%
净利率更高
CDNA
高出4.4%
-8.2%
两年增速更快
CDNA
近两年复合增速
21.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $7.7M | $108.4M |
| 净利润 | $-631.0K | $-4.1M |
| 毛利率 | 11.7% | — |
| 营业利润率 | -18.1% | -5.6% |
| 净利率 | -8.2% | -3.8% |
| 营收同比 | -14.8% | 25.2% |
| 净利润同比 | 52.5% | -104.7% |
| 每股收益（稀释后） | $-0.09 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMSCDNA
| Q4 25 | $7.7M | $108.4M | ||
| Q3 25 | $7.2M | $100.1M | ||
| Q2 25 | $7.1M | $86.7M | ||
| Q1 25 | $6.1M | $84.7M | ||
| Q4 24 | $9.1M | $86.6M | ||
| Q3 24 | $7.0M | $82.9M | ||
| Q2 24 | $7.1M | $92.3M | ||
| Q1 24 | $5.2M | $72.0M |
净利润AMSCDNA
| Q4 25 | $-631.0K | $-4.1M | ||
| Q3 25 | $-17.0K | $1.7M | ||
| Q2 25 | $-280.0K | $-8.6M | ||
| Q1 25 | $-625.0K | $-10.4M | ||
| Q4 24 | $-1.3M | $87.7M | ||
| Q3 24 | $-207.0K | $-10.6M | ||
| Q2 24 | $3.6M | $-4.6M | ||
| Q1 24 | $119.0K | $-19.9M |
毛利率AMSCDNA
| Q4 25 | 11.7% | — | ||
| Q3 25 | 22.1% | — | ||
| Q2 25 | 23.1% | — | ||
| Q1 25 | 15.4% | — | ||
| Q4 24 | 35.3% | — | ||
| Q3 24 | 19.6% | — | ||
| Q2 24 | 35.0% | — | ||
| Q1 24 | 41.1% | — |
营业利润率AMSCDNA
| Q4 25 | -18.1% | -5.6% | ||
| Q3 25 | -4.8% | -0.2% | ||
| Q2 25 | -7.7% | -12.8% | ||
| Q1 25 | -21.3% | -15.8% | ||
| Q4 24 | -20.2% | 97.5% | ||
| Q3 24 | -12.7% | -16.6% | ||
| Q2 24 | -0.0% | -7.9% | ||
| Q1 24 | -1.6% | -31.3% |
净利率AMSCDNA
| Q4 25 | -8.2% | -3.8% | ||
| Q3 25 | -0.2% | 1.7% | ||
| Q2 25 | -4.0% | -9.9% | ||
| Q1 25 | -10.2% | -12.2% | ||
| Q4 24 | -14.6% | 101.3% | ||
| Q3 24 | -3.0% | -12.8% | ||
| Q2 24 | 51.0% | -5.0% | ||
| Q1 24 | 2.3% | -27.6% |
每股收益（稀释后）AMSCDNA
| Q4 25 | $-0.09 | $-0.08 | ||
| Q3 25 | $0.00 | $0.03 | ||
| Q2 25 | $-0.04 | $-0.16 | ||
| Q1 25 | $-0.10 | $-0.19 | ||
| Q4 24 | $-0.21 | $1.60 | ||
| Q3 24 | $-0.03 | $-0.20 | ||
| Q2 24 | $0.55 | $-0.09 | ||
| Q1 24 | $0.02 | $-0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.5M | $177.2M |
| 总债务越低越好 | $17.4M | — |
| 股东权益账面价值 | $24.0M | $303.1M |
| 总资产 | $55.5M | $413.2M |
| 负债/权益比越低杠杆越低 | 0.72× | — |
8季度趋势，按日历期对齐
现金及短期投资AMSCDNA
| Q4 25 | $3.5M | $177.2M | ||
| Q3 25 | $5.1M | $194.2M | ||
| Q2 25 | $11.1M | $186.3M | ||
| Q1 25 | $11.2M | $230.9M | ||
| Q4 24 | $11.0M | $260.7M | ||
| Q3 24 | $13.8M | $240.9M | ||
| Q2 24 | $14.2M | $228.9M | ||
| Q1 24 | $12.8M | $215.9M |
总债务AMSCDNA
| Q4 25 | $17.4M | — | ||
| Q3 25 | $18.2M | — | ||
| Q2 25 | $19.1M | — | ||
| Q1 25 | $19.9M | — | ||
| Q4 24 | $20.4M | — | ||
| Q3 24 | $14.4M | $0 | ||
| Q2 24 | $15.1M | $0 | ||
| Q1 24 | $15.6M | — |
股东权益AMSCDNA
| Q4 25 | $24.0M | $303.1M | ||
| Q3 25 | $24.6M | $311.1M | ||
| Q2 25 | $24.5M | $327.4M | ||
| Q1 25 | $24.6M | $379.3M | ||
| Q4 24 | $25.2M | $378.4M | ||
| Q3 24 | $26.4M | $273.2M | ||
| Q2 24 | $26.5M | $264.7M | ||
| Q1 24 | $22.8M | $256.2M |
总资产AMSCDNA
| Q4 25 | $55.5M | $413.2M | ||
| Q3 25 | $59.6M | $432.3M | ||
| Q2 25 | $63.5M | $444.3M | ||
| Q1 25 | $63.3M | $489.6M | ||
| Q4 24 | $60.2M | $491.1M | ||
| Q3 24 | $63.3M | $477.0M | ||
| Q2 24 | $60.8M | $466.8M | ||
| Q1 24 | $50.1M | $452.4M |
负债/权益比AMSCDNA
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.74× | — | ||
| Q2 25 | 0.78× | — | ||
| Q1 25 | 0.81× | — | ||
| Q4 24 | 0.81× | — | ||
| Q3 24 | 0.54× | 0.00× | ||
| Q2 24 | 0.57× | 0.00× | ||
| Q1 24 | 0.68× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-704.0K | $21.4M |
| 自由现金流经营现金流 - 资本支出 | $-2.7M | — |
| 自由现金流率自由现金流/营收 | -34.8% | — |
| 资本支出强度资本支出/营收 | 25.7% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-8.5M | — |
8季度趋势，按日历期对齐
经营现金流AMSCDNA
| Q4 25 | $-704.0K | $21.4M | ||
| Q3 25 | $1.7M | $37.4M | ||
| Q2 25 | $-372.0K | $9.9M | ||
| Q1 25 | $2.5M | $-26.6M | ||
| Q4 24 | $274.0K | $21.9M | ||
| Q3 24 | $472.0K | $12.5M | ||
| Q2 24 | $1.3M | $18.9M | ||
| Q1 24 | $-1.9M | $-15.3M |
自由现金流AMSCDNA
| Q4 25 | $-2.7M | — | ||
| Q3 25 | $-2.0M | — | ||
| Q2 25 | $-2.3M | — | ||
| Q1 25 | $-1.5M | — | ||
| Q4 24 | $-4.4M | — | ||
| Q3 24 | $-407.0K | — | ||
| Q2 24 | $70.0K | — | ||
| Q1 24 | $-3.0M | — |
自由现金流率AMSCDNA
| Q4 25 | -34.8% | — | ||
| Q3 25 | -28.3% | — | ||
| Q2 25 | -32.1% | — | ||
| Q1 25 | -24.7% | — | ||
| Q4 24 | -48.4% | — | ||
| Q3 24 | -5.8% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | -58.4% | — |
资本支出强度AMSCDNA
| Q4 25 | 25.7% | — | ||
| Q3 25 | 51.6% | — | ||
| Q2 25 | 26.9% | — | ||
| Q1 25 | 65.7% | — | ||
| Q4 24 | 51.4% | — | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 17.2% | — | ||
| Q1 24 | 22.7% | — |
现金转化率AMSCDNA
| Q4 25 | — | — | ||
| Q3 25 | — | 22.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.36× | — | ||
| Q1 24 | -15.67× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMS
| Direct Patient Services | $4.0M | 51% |
| Rental Income From Medical Services | $2.7M | 35% |
| Pbrt Services | $1.2M | 15% |
CDNA
| Services | $78.4M | 72% |
| Patient And Digital Solutions | $16.8M | 15% |
| Products | $13.3M | 12% |
